Although the interleukin-17 inhibitor Ixekizumab is considered to have therapeutic potential for IBD, its critical role in maintaining epithelial barrier integrity and gut microbiota balance may explain the risk of IBD development during its treatment. This evidence concerns the gene IL17A and inflammatory bowel disease.